API CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Active Pharmaceutical Ingredients CDMO Market Trends and Companies. It is Segmented by Molecule Type (Small Molecule and Large Molecule), Synthesis (Biotech and Synthetic), Drug Type (Innovative and Generics), Workflow (Clinical and Commercial), Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Provides the Value (in USD) for the Above Segments.

API CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Active Pharmaceutical Ingredients CDMO Industry Overview

The active pharmaceutical ingredients CDMO market is fragmented and consists of several major players. In terms of market share, a few major players dominate the market. A few of them are Cambrex Corporation, Patheon (Themo Fisher Scientific Inc.), Recipharm AB, Astorg (CordenPharma), Samsung Biologics, Lonza, Siegfried, Piramal Pharma Solutions, Abbvie Inc., and Catalent Inc.

The role of API manufacturers in the pharmaceutical supply chain is evolving in response to customers' newfound demands and increasing pressures from global competitors. Traditional generic firms are looking to China and India for bulk activities, while specialty pharmaceutical companies have generated new demands for more specialized capabilities than traditional generics require.

Active Pharmaceutical Ingredients CDMO Market Leaders

  1. Catalent, Inc.

  2. Cambrex Corporation

  3. Lonza Group

  4. Recipharm AB

  5. Astorg (Corden Pharma)

  6. *Disclaimer: Major Players sorted in no particular order
Active Pharmaceutical Ingredients CDMO Market Concentration

Active Pharmaceutical Ingredients CDMO Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?